Effect of V0251 in Acute Vertigo

• Status: Completed
• Trial end date: 2013-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Assessment of efficacy and tolerance of a new anti-dizziness drug in acute vertigo.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pierre Fabre Medicament

Criteria

Inclusion Criteria:

• Men or women

• Age 18 to 70 years

• Acute vertigo attack due to vestibular disorder

Exclusion Criteria:

• Signs of brain, brainstem and/or cerebellar dysfunction

• Concomitant central neurological disorder

• Psychogenic vertigo

• Use of ototoxic drugs causing vertigo or dizziness within the last month

• Use of anti-dizziness medications from the onset of symptoms, except if the dosage had been stable for at least 3 months